[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

A director of Orchestra BioMed Holdings, Inc. (OBIO) reported a purchase of company common stock on 09/19/2025. The Form 4 shows 1,000 shares were acquired at $2.45 per share, bringing the reporting persons beneficial ownership to 108,482 shares, held directly. The filing was signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Insider purchase disclosed which increases the reporting directors direct ownership to 108,482 shares
• Clear compliance with Section 16 reporting: transaction date, price ($2.45), and post-transaction holdings are provided

Negative

• Transaction size is small (1,000 shares) and not likely material to investors
• No additional context such as reason for purchase or total outstanding shares is provided in the filing

Insights

Corporate Governance Expert

TL;DR: Director purchased a small block of shares, modestly increasing direct ownership to 108,482 shares.

The transaction is a straightforward open-market purchase: 1,000 common shares at $2.45 on 09/19/2025. As reported on Form 4, the ownership is direct and the filing was executed by an attorney-in-fact. This disclosure complies with Section 16 reporting requirements and contains no additional terms, derivatives, or contingent arrangements.

Securities Analyst

TL;DR: Insufficient size to be materially market-moving; routine insider purchase disclosed.

The purchase size (1,000 shares) relative to the total reported holding (108,482 shares) is small. The Form 4 provides transaction date, price, and post-transaction ownership, with no amendments or derivative instruments reported. No further financial metrics or context are provided in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aryeh Jason

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	09/19/2025		P		1,000	A	$2.45	108,482	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Andrew Taylor, Attorney-in-Fact	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OBIO insider buy on 09/19/2025?

The reporting director purchased 1,000 shares of Orchestra BioMed (OBIO) common stock at $2.45 per share on 09/19/2025.

How many OBIO shares does the reporting person own after the transaction?

The Form 4 reports 108,482 shares beneficially owned following the reported purchase.

Was the OBIO Form 4 filed jointly or individually?

The filing indicates it was submitted by one reporting person (individual filing).

Is the ownership direct or indirect according to the filing?

The Form 4 specifies the ownership form as Direct (D).

Who signed the Form 4 for the reporting person?

The Form 4 was signed by /s/ Andrew Taylor, Attorney-in-Fact on 09/19/2025.